Email RIS file
Bookmark
Report an Issue

Cost-effectiveness of a HPV-vaccination catch-up program for females aged 26 years or younger in a Norwegian setting [electronic resource] / Jime<U+0301>nez, Enrique, Wislf̜f, Torbjr̜n, Klemp, Marianne

Author
Jime<U+0301>nez, Enrique (Of Nasjonalt kunnskapssenter for helsetjenesten)
Additional Titles
Title in Norwegian: <U+00D8>konomisk evaluering av en innhentingsvaksine mot HPV for kvinner under 26 a<U+030A>r
Published
Oslo : Norwegian Knowledge Centre for the Health Services, March 2014.
Physical Description
1 online resource (1 PDF file (91 pages)) : illustrations
Additional Creators
Wislf̜f, Torbjr̜n, Klemp, Marianne, and Nasjonalt kunnskapssenter for helsetjenesten
Access Online

Availability

I Want It
I Want It

Finding items...

Series
Language Note
Text in English; summaries in English and Norwegian.
Restrictions on Access
License restrictions may limit access.
Summary
Infection with human papillomavirus (HPV) is documented to be associated with several precancerous lesions (CIN, VIN and VaIN), cancer and genital warts. In this economic evaluation, we evaluated the cost-effectiveness of administering a catch-up vaccine to females aged 26 years or younger in addition to the current practice of vaccinating 12 year-old- girls compared to maintaining the current practice. Currently, two vaccines are available in the Norwegian market with documented effect against HPV-infection: the quadrivalent vaccine, directed at HPV 6, 11, 16 and 18, and the bivalent vaccine, directed at HPV 16 and 18. In this report, we estimated the cost-effectiveness of the quadrivalent vaccine for the target population. The cost-effectiveness of the bivalent vaccine is nevertheless discussed in one of the scenario analyses we conducted. The main results of the evaluation are the following:1. From a public health budget perspective and given the current public price of NOK 1 010.9/dose of the quadrivalent vaccine, introducing a catch-up vaccine for the target population is cost-effective if one is willing to pay NOK 578 391 for a gained quality-adjusted life-year (QALY).2. For a willingness-to-pay of NOK 578 391/QALY and from a public health budget perspective, the bivalent vaccine may be considered cost-effective if its price is no higher than approximately NOK 780/dose.3. From a societal perspective, i.e. when costs to patients for time used under treatment and the work-related productivity costs due to disease are included, the catch-up vaccine is cost-effective if one is willing to pay NOK 553 691 per gained QALY.
Subject(s)
Genre(s)
ISBN
9788281218512
Bibliography Note
Includes bibliographical references.
View MARC record | catkey: 44547474